Immunotherapy of cancer with alloreactive lymphocytes.
Immunotherapy of cancer with alloreactive lymphocytes is the mainstay of treatment, especially in haematological malignant disease. With donor lymphocyte infusion for immunotherapy, it is essential to induce host-versus-graft tolerance to ensure that the donor lymphocytes are accepted. Engraftment of haemopoietic cells of donor origin can be accomplished with reduced-intensity conditioning. Reducing transplant-related mortality by simplifing the stem-cell transplant procedure with a reduced-intensity regimen, particularly non-myeloablative conditioning, may have great potential for the treatment of malignant and non-malignant disorders.
Slavin
S
S
Department of Bone Marrow Transplantation & Cancer Immunotherapy, Hadassah University Hospital, Ein Karem Jerusalem, Israel. slavin@cc.huji.ac.il
D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D017710:Lymphocyte Transfusion; D008214:Lymphocytes / Q000276:immunology*; D009369:Neoplasms / Q000628:therapy*